Can Premium Hair Care Match Skin-Care Growth Trajectory?
This article was originally published in The Rose Sheet
Executive Summary
Euromonitor senior beauty analyst Oru Mohiuddin considers premium hair care’s prospects for realizing growth on par with premium skin care in recent years. Factors that may impede the category’s growth at the same level as skin care include differences in consumer perception and regulatory restrictions.
You may also be interested in...
J&J Pits 5% Minoxidil Rogaine For Women Against ‘Cosmetic, Quick Fixes’
Firm’s McNeil-PPC subsidiary has patent exclusivity for Women’s Rogaine with the higher concentration of minoxidil through February 2017, tightening its grip on a market that cosmetics firms have struggled to penetrate effectively in the United States. According to a brand consultant and dermatologist, the new Rogaine offering actually helps regrow hair rather than merely “masking” the issue.
Dermocosmetic Market Ripens With Uptake Of FDA-Approved Drug Ingredients
The market for specialized dermocosmetics is expanding rapidly as big beauty marketers join the fray with products containing OTC-approved drug ingredients for hair and skin care, says Euromonitor Beauty & Personal Care analyst Nicholas Micallef. Coal tar, ketoconazole and salicylic acid are among approved drug ingredients increasingly making their way into beauty.
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry
EAS Consulting rep John Bailey, who directed FDA’s cosmetics program in the 1990s and served as PCPC chief scientist through July of 2011, offers his view on the six warning letters issued to cosmetics firms between Sept. 7 and Oct. 5. It’s too early to say whether FDA is taking a more aggressive stance on cosmetics claims, but firms “need to be aware,” Bailey says.